Clinical trial
A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have…
NCT00002217 · Glaxo Wellcome, Industry · Completed
Key facts
| NCT number | NCT00002217 |
|---|---|
| Title | A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs |
| Official title | Combivir, 1592U89, 141W94 Triple Antiretroviral, Experienced Patient Trial |
| Lead sponsor | Glaxo Wellcome, Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Lamivudine/Zidovudine, Abacavir sulfate, Amprenavir |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: